Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Clinically significant drug interactions with agents specific for migraineattacks
Autore:
Eadie, MJ;
Indirizzi:
Univ Queensland, Dept Med, Royal Brisbane Hosp, Brisbane, Qld, Australia Univ Queensland Brisbane Qld Australia ne Hosp, Brisbane, Qld, Australia
Titolo Testata:
CNS DRUGS
fascicolo: 2, volume: 15, anno: 2001,
pagine: 105 - 118
SICI:
1172-7047(2001)15:2<105:CSDIWA>2.0.ZU;2-L
Fonte:
ISI
Lingua:
ENG
Soggetto:
ANTIMIGRAINE COMPOUND ZOLMITRIPTAN; HEALTHY-VOLUNTEERS; MACROLIDE ANTIBIOTICS; SEROTONIN SYNDROME; PHARMACOKINETIC INTERACTION; ERGOTAMINE INTERACTION; CYTOCHROME-P450 3A4; LIVER-MICROSOMES; CONCOMITANT USE; BETA-BLOCKERS;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
100
Recensione:
Indirizzi per estratti:
Indirizzo: Eadie, MJ Ladhope Chambers, 131 Wickham Tce, Brisbane, Qld, Australia Ladhope Chambers 131 Wickham Tce Brisbane Qld Australia stralia
Citazione:
M.J. Eadie, "Clinically significant drug interactions with agents specific for migraineattacks", CNS DRUGS, 15(2), 2001, pp. 105-118

Abstract

The drugs which provide specific relief from migraine attacks, the ergopeptides (ergotamine and dihydroergotamine) and the various 'triptans' (notably sumatriptan), are often prescribed for persons already taking various migraine preventative agents, and sometimes drugs for other indications. As a result, migraine-specific drugs may become involved in drug-drug interactions. The migraine-specific drugs all act as agonists at certain subclasses of serotonin (5-hydroxytryptamine; 5-MT) receptor, particularly those of the 5-HT1D subtype, and produce vasoconstriction through these receptor-mediated mechanisms. The oral bioavailabilities of these drugs, particularly those of the ergopeptides, are often incomplete, due to extensive presystemic metabolism. As a result, if migraine-specific agents are coadministered with drugs with vasoconstrictive properties, or with drugs which inhibit the metabolism of the migraine-specific agents, there is a risk of interactions occurring which produce manifestations of excessive vasoconstriction. This can also occur through pharmacodynamic mechanisms, as when ergopeptides or triptans are coadministered with methysergide or propranolol (although a pharmacokinetic element may apply in relation to the latter interaction), or if one migraine-specific agent is used shortly after another. When egopeptide metabolism is inhibited by the presence of macrolide antibacterials, particularly troleandomycin and erythromycin, the resultant interaction can produce ergotism, sometimes leading to gangrene. Similar pharmacokinetic mechanisms, with their vasoconstrictive consequences, probably apply to combination of the ergopeptides with HIV protease inhibitors (indinavir and ritonavir), heparin, cyclosporin or tacrolimus. Inhibition of triptan metabolism by monoamine oxidase A inhibitors, e.g. moclobemide, may raise circulating triptan concentrations, although this does not yet seem to have led to reported clinical problems. Caffeine may cause increased plasma ergotamine concentrations through an as yet inadequately defined pharmacokinetic interaction. However, a direct antimigraine effect of caffeine may contribute to the claimed increased efficacy of ergotamine-caffeine combinations in relieving migraine attacks. Serotonin syndromes have been reported as probable pharmacodynamic consequences of the use of ergots or triptans in persons taking serotonin reuptakeinhibitors. There have been two reports of involuntary movement disorders when sumatriptan has been used by patients already taking loxapine. Nearly all the clinically important interactions between the ergopeptide antimigraine agents and currently marketed drugs are likely to have already come to notice. In contrast, new interactions involving the triptans are likely to be recognised as additional members of this family of drugs, with their different patterns of metabolism and pharmacokinetics, are marketed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 09:48:15